Section 6 of 6
References
63 sources
- AAAAI (2025) (opens in a new tab)
- AAAAI (2026) (opens in a new tab)
- Akin (2023) (opens in a new tab)
- Akin et al. (2026a) (opens in a new tab)
- Akin et al. (2026b) (opens in a new tab)
- ASH (2022) (opens in a new tab)
- AYVAKIT prescribing information (2023) (opens in a new tab)
- Blood (2023) (opens in a new tab)
- Boggs et al. (2026) (opens in a new tab)
- Bose et al. (2026) (opens in a new tab)
- Bulai Livideanu et al. (2025) (opens in a new tab)
- Canada’s Drug Agency avapritinib reimbursement recommendation (2026) (opens in a new tab)
- Canada’s Drug Agency avapritinib reimbursement review report (2026) (opens in a new tab)
- Chifotides and Bose (2025) (opens in a new tab)
- ClinicalTrials.gov NCT05186753 (opens in a new tab)
- Cogent Biosciences (opens in a new tab)
- Cogent Biosciences 2026 AAAAI additional SUMMIT data announcement (2026) (opens in a new tab)
- Cogent Biosciences 2026 AAAAI SUMMIT posters announcement (2026) (opens in a new tab)
- Cogent Biosciences AdvSM new drug application acceptance announcement (2026) (opens in a new tab)
- Cogent Biosciences Breakthrough Therapy designation announcement (2025) (opens in a new tab)
- Cogent Biosciences first quarter 2026 financial results (2026) (opens in a new tab)
- Cogent Biosciences investor overview (opens in a new tab)
- Cogent Biosciences NonAdvSM new drug application acceptance announcement (2026) (opens in a new tab)
- Cogent Biosciences NonAdvSM new drug application submission announcement (2025) (opens in a new tab)
- Cogent Biosciences presentation (2024) (opens in a new tab)
- Cogent Biosciences presentation (2025) (opens in a new tab)
- Cogent Biosciences second quarter 2026 results announcement (2026) (opens in a new tab)
- Cogent Biosciences SUMMIT full results announcement at ASH (2025) (opens in a new tab)
- Cogent Biosciences SUMMIT top-line results announcement (2025) (opens in a new tab)
- Cogent Biosciences third quarter 2026 financial results (2026) (opens in a new tab)
- Costa et al. (2023) (opens in a new tab)
- Costanzo et al. (2025) (opens in a new tab)
- Dana-Farber Cancer Institute (opens in a new tab)
- Fahrenholz et al. (2026) (opens in a new tab)
- Farmer and Radia (2024) (opens in a new tab)
- FDA orphan drug designation record for avapritinib (2023) (opens in a new tab)
- FDA orphan drug designation record for bezuclastinib (2023) (opens in a new tab)
- George et al. (2025) (opens in a new tab)
- George et al. (2026) (opens in a new tab)
- Gotlib et al. (2023) (opens in a new tab)
- Guarnieri et al. (2021) (opens in a new tab)
- IQWiG (opens in a new tab)
- Jørgensen et al. (2025) (opens in a new tab)
- Marcus et al. (2026) (opens in a new tab)
- McMurray et al. (2024) (opens in a new tab)
- MD Anderson Cancer Center (opens in a new tab)
- Mesa et al. (2022a) (opens in a new tab)
- Mesa et al. (2022b) (opens in a new tab)
- NCCN (2024) (opens in a new tab)
- Norregaard et al. (2021) (opens in a new tab)
- Patent WO2024138005A1 (2024) (opens in a new tab)
- Pongdee et al. (2025) (opens in a new tab)
- Pongdee et al. (2026) (opens in a new tab)
- Rein et al. (2024) (opens in a new tab)
- Rein et al. (2025) (opens in a new tab)
- Rein et al. (2026a) (opens in a new tab)
- Rein et al. (2026b) (opens in a new tab)
- Siebenhaar et al. (2025a) (opens in a new tab)
- Siebenhaar et al. (2025b) (opens in a new tab)
- Syal et al. (2025) (opens in a new tab)
- Tse et al. (2024) (opens in a new tab)
- Valent et al. (2021) (opens in a new tab)
- Zeiger et al. (2025) (opens in a new tab)